sibeprenlimab

Latest news

Tag

Sibeprenlimab Demonstrates Kidney Function Preservation in IgA Nephropathy: Insights from the Final Phase 3 VISIONARY Trial

The phase 3 VISIONARY trial establishes sibeprenlimab as a promising therapy in IgA nephropathy, significantly stabilizing eGFR decline and reducing kidney-function deterioration over 24 months with a favorable safety profile.

Oct 30, 2026

Internal Medicine

Sibeprenlimab Achieves 51% Reduction in Proteinuria for IgA Nephropathy: Key Interim Insights from the Phase 3 VISIONARY Trial

The Phase 3 VISIONARY trial interim analysis demonstrates that sibeprenlimab, a monoclonal antibody targeting APRIL, significantly reduces proteinuria and pathogenic IgA1 in patients with IgA nephropathy, offering a promising upstream thera

Feb 22, 2026

Allergy & Immunology

Emerging APRIL-Targeted Therapies in IgA Nephropathy and IgA Vasculitis Nephritis: Clinical Advances with Zigakibart, Sibeprenlimab, and Telitacicept

Recent clinical trials of APRIL-targeted monoclonal antibodies—zigakibart, sibeprenlimab, and telitacicept—demonstrate safety and significant proteinuria reduction in IgA nephropathy and IgA vasculitis nephritis, offering promising disease-

Aug 24, 2025